Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FH-WT1-E50 TCR T-cells |
| Synonyms | |
| Therapy Description |
FH-WT1-E50 TCR T-cells are autologous HLA-A*02:01-restricted CD4/CD8-positive T-lymphocytes expressing a T-cell receptor targeting WT1 and a CD8alpha/beta co-receptor, which potentially induces an antitumor immune response against WT1-expressing tumors (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FH-WT1-E50 TCR T-cells | FH WT1-E50 TCR T-cells|FH-WT1-E50 TCR T cells | FH-WT1-E50 TCR T-cells are autologous HLA-A*02:01-restricted CD4/CD8-positive T-lymphocytes expressing a T-cell receptor targeting WT1 and a CD8alpha/beta co-receptor, which potentially induces an antitumor immune response against WT1-expressing tumors (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07645469 | Phase I | FH-WT1-E50 TCR T-cells Azacitidine | FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia | Not yet recruiting | USA | 0 |